Citations

Clear

391 citation(s) found for "Bi, Chun".

Pleural “drop metastases” 21 years after resection of a thymoma
Chiang, Chia‐Chun , Parsons, Angela, Kriegshauser, J. Scott , Paripati, Harshita, Zarka, Matthew A., Leis, A. Arturo , Parsons, Angela M, Paripati, Harshita R, Kriegshauser, J Scott , Chiang, Chia-Chun

Mayo Clinic

Muscle & Nerve | November 16, 2016 | Volume: 56 | Issue: 1 | Pages: 171-175

10.1002/mus.25479 | PMID 27862032 Get It

ABSTRACTIntroduction: We describe an unusual case of pleural drop metastases 21 years after complete resection of an encapsulated thymoma in a Southeast Asian patient with myasthenia gravis (MG). Methods: This investigation includes a case report and brief review of the literature. Results: The patient presented in 2015 with generalized weakness, fatigue, and shortness of breath, but no diplopia, ptosis, dysphagia, or dysarthria. Because these symptoms were atypical for an MG exacerbation, a de‐novo work‐up was performed. Chest computed tomography (CT) showed numerous pleural nodules (“drop metastases”), and CT‐guided biopsy revealed metastatic thymoma. Conclusions: The average disease‐free interval for thymoma ranges from 68 to 86 months. Pleural and mediastinal recurrence are more common than distant hematogenous recurrence. Adverse prognostic factors include an initial higher Masaoka stage, incomplete resection, older age, and pleural or pericardial involvement. Despite apparent complete resection of thymoma, clinicians should remain vigilant for recurrence for as long as 20 years after initial management. Long‐term follow‐up with radiologic surveillance is recommended. Muscle Nerve 56: 171–175, 2017
A New Vertebral Body Replacement Strategy Using Expandable Polymeric Cages
Liu, Xifeng , Paulsen, Alex R., Giambini, Hugo , Guo, Ji, Lin, Po-Chun, Yaszemski, Michael J. , Lu, Lichun , Paulsen, Alex, Miller, A. Lee , Miller, Alan Lee

Mayo Clinic

Tissue Engineering Part A | November 12, 2016 | Volume: 23 | Issue: 5-6 | Pages: 223-232

10.1089/ten.tea.2016.0246 | PMID 27835935 Get It

Treatment of Unstable Posterior Pelvic Ring Fracture with Pedicle Screw-Rod Fixator Versus Locking Compression Plate: A Comparative Study
Bi, Chun, Wang, Qiugen , Nagelli, Christopher V. , Wu, Jianhong, Wang, Qian , Wang, Jiandong , Nagelli, Christopher, Wu, Jianhong

Mayo Clinic

Medical Science Monitor | October 17, 2016 | Volume: 22 | Issue: No issue available | Pages: 3764-3770

10.12659/msm.900673 | PMID 27748355 Get It

Noninvasive Failure Load Prediction of Vertebrae with Simulated Lytic Defects and Biomaterial Augmentation
Giambini, Hugo , Fang, Zhong , Camp, Jon J. , Yaszemski, Michael J. , Zeng, Heng, Zeng, Heng, Lu, Li‐Chun

Mayo Clinic

Tissue Engineering Part C: Methods | June 4, 2016 | Volume: 22 | Issue: 8 | Pages: 717-724

10.1089/ten.tec.2016.0078 | PMID 27260559 Get It

The spine is the most common site for secondary bone metastases, and clinical management for fractures is based on size and geometry of the defect. About 75% of the bone needs to be damaged before lesions are detectable, so clinical tools should measure changes in both geometry and material properties. We have developed an automated, user-friendly, Spine Cancer Assessment (SCA) image-based analysis method that builds on a platform designed for clinical practice providing failure characteristics of vertebrae. The objectives of this study were to (1) validate SCA predictions with experimental failure load outcomes; (2) evaluate the planning capabilities for prophylactic vertebroplasty procedures; and (3) investigate the effect of computed tomography (CT) protocols on predicted failure loads. Twenty-one vertebrae were randomly divided into two groups: (1) simulated defect without treatment (negative control) [ n = 9] and (2) with treatment [ n = 12]. Defects were created and a polymeric biomaterial was injected into the vertebrae in the treated-defect group. Spines were scanned, reconstructed with two algorithms, and analyzed for fracture loads. To virtually plan for prophylactic intervention, vertebrae with empty lesions were simulated to be augmented with either poly(methyl methacrylate) (PMMA) or a novel bone replacement copolymer, poly(propylene fumarate-co-caprolactone) [P(PF-co-CL)]. Axial rigidities were calculated from the CT images. Failure loads, determined from the cross section with the lowest axial rigidity, were compared with experimental values. Predicted loads correlated well with experimental outcomes ( R 2 = 0.73, p < 0.0001). Predictions from negative control specimens highly correlated with measured values ( R 2 = 0.90, p < 0.0001). Although a similar correlation was obtained using both algorithms, the smooth reconstruction (B30) tended to underestimate predicted failure loads by ∼50% compared with the ∼10% underestimate of the sharp reconstruction (B70). Percent increase in failure loads after virtual vertebroplasty showed a higher increase in samples with PMMA compared with those with copolymer. The SCA method developed in this study calculated failure loads from quantitative computed tomography scans in vertebrae with simulated metastatic lytic defects, with or without treatment, facilitating clinical applicability and providing more reliable guidelines for physicians to select appropriate treatment options. Furthermore, the analysis could accommodate augmentation planning procedures that aimed to determine the optimum material that would increase vertebral body failure load.
Social and behavioural factors associated with frailty trajectories in a population-based cohort of older adults
Chamberlain, Alanna M. , Sauver, Jennifer L. St. , Jacobson, Debra J., Manemann, Sheila M., Fan, Chun , Roger, Véronique L. , Yawn, Barbara P. , St Sauver, Jennifer L, Finney Rutten, Lila J, Rutten, Lila J. Finney , St Sauver, Jennifer L , Chamberlain, Alanna M

Mayo Clinic

BMJ Open | May 27, 2016 | Volume: 6 | Issue: 5 | Pages: e011410

10.1136/bmjopen-2016-011410 | PMID 27235302 Get It

Objective The goal of this study was to identify distinct frailty trajectories (clusters of individuals following a similar progression of frailty over time) in an ageing population and to determine social and behavioural factors associated with frailty trajectories. Design Population-based cohort study. Setting Olmsted County, Minnesota. Participants Olmsted County, Minnesota residents aged 60–89 in 2005. Primary outcome measure Changes in frailty over an 8-year period from 2005 to 2012, measured by constructing a yearly frailty index. Frailty trajectories by decade of age were determined using k-means cluster modelling for longitudinal data. Results After adjustment for age and sex, all social and behavioural factors (education, marital status, living arrangements, smoking status and alcohol use) were significantly associated with frailty trajectories in those aged 60–69 and 70–79 years. After further adjustment for baseline frailty, the likelihood of being in the high frailty trajectory was greatest among those reporting concerns from relatives/friends about alcohol consumption (OR (95% CI) 2.26 (1.19 to 4.29)) and those with less than a high school education (OR (95% CI) 1.98 (1.32 to 2.96)) in the 60–69 year olds. In the 70–79 year olds, the largest associations were observed among those with concerns from oneself about alcohol consumption (OR (95% CI) 1.92 (1.23 to 3.00)), those with less than a high school education (OR (95% CI) 1.57 (1.12 to 2.22)), and those living with family (vs spouse; OR (95% CI) 1.76 (1.05 to 2.94)). No factors remained associated with frailty trajectories in the 80–89 year olds after adjustment for baseline frailty. Conclusions Social and behavioural factors are associated with frailty, with stronger associations observed in younger ages. Recognition of social and behavioural factors associated with increasing frailty may inform interventions for individuals at risk of worsening frailty, specifically when targeted at younger individuals.
Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities
Pistollato, Francesca , Ohayon, Elan, Lam, Ann , Langley, Gillian R. , Novak, Thomas J., Pamies, David , Perry, George , Trushina, Eugenia , Williams, Robin S. B. , Roher, Alex E., Härtung, Thomas , Morris, Martha Clare, Lai, Mei-Chun, Merkley, Ryan, Chandrasekera, P. Charukeshi, Harnad, Stevan R. , Barnard, Neal D. , Trushina, Eugenia

Mayo Clinic

Oncotarget | May 6, 2016 | Volume: 7 | Issue: 26 | Pages: 38999-39016

10.18632/oncotarget.9175 | PMID 27229915 Get It

Education on, Exposure to, and Management of Vascular Anomalies During Otolaryngology Residency and Pediatric Otolaryngology Fellowship
Jabbour, Noel , Balakrishnan, Karthik , Darrow, David H., Elluru, Ravindhra G., Grimmer, J. Fredrik , Richter, Gresham T. , Shin, Jennifer J. , Chun, Robert H. , Bauman, Nancy M. , Perkins, Jonathan A. , Balakrishnan, Karthik

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | April 28, 2016 | Volume: 142 | Issue: 7 | Pages: 648

10.1001/jamaoto.2016.0605 | PMID 27124736 Get It

JNK2 downregulation promotes tumorigenesis and chemoresistance by decreasing p53 stability in bladder cancer
Pan, Chun-Wu, Liu, Hailong , Qian, Chenchen , Wang, Liguo , Qi, Jun , Zhao, Yu , Wang, Liguo

Mayo Clinic

Oncotarget | April 27, 2016 | Volume: 7 | Issue: 23 | Pages: 35119-35131

10.18632/oncotarget.9046 | PMID 27147566 Get It

Frailty Trajectories in an Elderly Population‐Based Cohort
Chamberlain, Alanna M. , Manemann, Sheila M., Yawn, Barbara P. , Jacobson, Debra J., Fan, Chun , Grossardt, Brandon R. , Roger, Véronique L. , Sauver, Jennifer L. St. , Finney Rutten, Lila J, St Sauver, Jennifer L, Rutten, Lila J. Finney , St Sauver, Jennifer L , Chamberlain, Alanna M , Grossardt, Brandon R

Mayo Clinic

Journal of the American Geriatrics Society | February 20, 2016 | Volume: 64 | Issue: 2 | Pages: 285-292

10.1111/jgs.13944 | PMID 26889838 Get It

Objectives To identify distinct frailty trajectories (clusters of individuals following a similar progression of frailty over time) in an aging population and to estimate associations between frailty trajectories and emergency department visits, hospitalizations, and all‐cause mortality. Design Population‐based cohort study. Setting Olmsted County, Minnesota. Participants Olmsted County, Minnesota residents aged 60–89 in 2005. Measurements Longitudinal changes in frailty between 2005 and 2012 were measured by constructing a yearly Rockwood frailty index incorporating body mass index, 17 comorbidities, and 14 activities of daily living. The frailty index measures variation in health status as the proportion of deficits present of the 32 considered (range 0–1). Results Of the 16,443 Olmsted County residents aged 60–89 in 2005, 12,270 (74.6%) had at least 3 years of frailty index measures and were retained for analysis. The median baseline frailty index increased with age (0.11 for 60–69, 0.14 for 70–79, 0.19 for 80–89). Three distinct frailty trajectories were identified in individuals aged 60–69 at baseline and two trajectories in those aged 70–79 and 80–89. Within each decade of age, increasing frailty trajectories were associated with greater risks of emergency department visits, hospitalization, and all‐cause mortality, even after adjustment for baseline frailty index. Conclusion The number of frailty trajectories differed according to age. Within each age group, those in the highest frailty trajectory had greater healthcare use and worse survival. Frailty trajectories may offer a way to target aging individuals at high risk of hospitalization or death for therapeutic or preventive interventions.
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Diamond, Eli L. , Durham, Benjamin H. , Haroche, Julien , Yao, Zhan , Ma, Jing , Wang, Zhaoming , Choi, John , Kim, Eun Hee , Cohen‐Aubart, Fleur , Lee, Stanley Chun-Wei , Gao, Yijun , Micol, Jean‐Baptiste , Campbell, Patrick , Walsh, Michael P. , Sylvester, Brooke E., Dolgalev, Igor , Aminova, Olga, Heguy, Adriana , Zappile, Paul, Nakitandwe, Joy , Ganzel, Chezi , Dalton, James , Ellison, David W. , Estrada‐Veras, Juvianee , Lacouture, Mario E. , Gahl, William A. , Stephens, Philip J., Miller, Vincent A. , Ali, Siraj M. , Briggs, Samuel, Fasan, Omotayo , Block, Jared , Héritier, Sébastien , Solit, David B. , Hyman, David M. , Baselga, José , Jankú, Filip , Taylor, Barry S. , Amoura, Zahir , Rosen, Neal , Parikh, Sameer A. , Ross, Jeffrey S , Donadieu, Jean , Park, Christopher Y. , Doǧan, Ahmet , Emile, Jean‐François , Gruber, Tanja Andrea , Abdel‐Wahab, Omar , Diamond, Eli L , Wang, Zhaoming , Héritier, Sébastien , Durham, Benjamin

Mayo Clinic

Cancer Discovery | November 13, 2015 | Volume: 6 | Issue: 2 | Pages: 154-165

10.1158/2159-8290.cd-15-0913 | PMID 26566875 Get It

Abstract Histiocytic neoplasms are clonal, hematopoietic disorders characterized by an accumulation of abnormal, monocyte-derived dendritic cells or macrophages in Langerhans cell histiocytosis (LCH) and non-Langerhans cell histiocytosis (non-LCH), respectively. The discovery of BRAFV600E mutations in approximately 50% of these patients provided the first molecular therapeutic target in histiocytosis. However, recurrent driving mutations in the majority of patients with BRAFV600E–wild-type non-LCH are unknown, and recurrent cooperating mutations in non-MAP kinase pathways are undefined for the histiocytic neoplasms. Through combined whole-exome and transcriptome sequencing, we identified recurrent kinase fusions involving BRAF, ALK, and NTRK1, as well as recurrent, activating MAP2K1 and ARAF mutations in patients with BRAFV600E–wild-type non-LCH. In addition to MAP kinase pathway lesions, recurrently altered genes involving diverse cellular pathways were identified. Treatment of patients with MAP2K1- and ARAF-mutated non-LCH using MEK and RAF inhibitors, respectively, resulted in clinical efficacy, demonstrating the importance of detecting and targeting diverse kinase alterations in these disorders. Significance: We provide the first description of kinase fusions in systemic histiocytic neoplasms and activating ARAF and MAP2K1 mutations in non-Langerhans histiocytic neoplasms. Refractory patients with MAP2K1- and ARAF-mutant histiocytoses had clinical responses to MEK inhibition and sorafenib, respectively, highlighting the importance of comprehensive genomic analysis of these disorders. Cancer Discov; 6(2); 154–65. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 109